CELLPOINT-DIGITAL
25.4.2022 01:03:06 CEST | Business Wire | Press release
CellPoint Digital , a leading global provider of digital commerce and payment solutions, today announces a partnership with global eCommerce platform for video gamers, MTC Game .
An international retailer, MTC Game provides an online platform for digital codes and services to gamers.
The company will take advantage of CellPoint Digital’s payment orchestration platform. This will enable video gamers, initially in Africa but with plans to expand further, to experience a frictionless checkout, allowing customers to pay via the popular payment methods on the continent including Bank Transfer and Mobile Money options.
By orchestrating payments across Africa, CellPoint Digital is allowing MTC Game to adopt a multi-acquirer payments model that will ultimately open up new opportunities for growth. As a result, CellPoint Digital will help increase MTC Game’s top-line revenue by utilising intelligent routing, increasing authorisations, and providing system uptime transparency, as well as reduce the operational cost of accepting cross border payments.
Sinan BAĞ, Business Development Manager, at MTC Game commented: “ The video game industry is one of the largest media sectors in the world, with gamers in every market. We are excited to expand our payment offering for customers in Africa as we know it will give players in the region more seamless access to the games they want to enjoy.
“CellPoint Digital has been hugely supportive in making this happen. Their close consultative approach on which cross-border payment partners we need to approach, and how to best utilise their platform to meet our market goals, has been indispensable. We look forward to adding more payment methods to our platform and taking on new territories together with the CellPoint Team.”
Kristian Gjerding, CEO of CellPoint Digital added: “In regions like Africa, where video game consoles from all three major markets can be found, it is pivotal for sellers to let their consumers pay with currencies and methods beyond their local options. By partnering with MTC Game, we are helping our new partner with its expansion plans. The video game sector has always felt like a natural extension of our success in the gambling and retail industries, and we are excited to disrupt payments in this dynamic vertical.”
Currently, Africa is MTC Game’s initial market utilising CellPoint Digital’s payment orchestration platform, however as the partnership continues, the potential benefits this change brings will help them expand into other regions as well.
#END#
About CellPoint Digital
CellPoint Digital is a fintech leader in payment orchestration. CellPoint Digital’s main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rates and minimise payment costs.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore. Visit www.cellpointdigital.com to learn more.
About MTC Game
MTC Games or commonly known as MTCGAME is an international online platform which provides digital codes and services to gamers.
Being in the industry over two decades, we are in service of more than 5.000.000 active users worldwide. To offer a better service for our customers, we provide 24/7 online Live Support.
By means of trustworthy service, years of experience in the game industry, and also with variety of local and global payment methods provided, we have grown into one of the most reliable online gaming hub. As MTCGAME, we keep growing by adding new games and partners into our structure.
To discover more visit our portal: www.mtcgame.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom